Kingdon Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Kingdon Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-941,348	Closed	-$1.63M	–	150
2016 Q4	$1.63M	Sell	941,348 -17,474	-2%	-$30.8K	0.08%	112
2016 Q3	$1.86M	Hold	958,822	–	–	0.09%	102
2016 Q2	$1.67M	Sell	958,822 -98	-0%	-$203	0.09%	93
2016 Q1	$1.29M	Sell	958,920 -35,000	-4%	-$43.4K	0.07%	100
2015 Q4	$1.68M	Buy	993,920 +43,920	+5%	+$71.6K	0.08%	105
2015 Q3	$1.84M	Buy	+950,000	New	+$2.59M	0.09%	108

Other funds holding CBAY

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Kingdon Capital Management's CBAY Position: Q1 2017 in Review

Kingdon Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2017, closing a stake of 941,348 shares — an estimated $1.63M sold.

Kingdon Capital Management first reported a position in CBAY in Q3 2015 and held it in 6 quarters. The position peaked at $1.86M in Q3 2016. 34 funds tracked by Wall St. Rank hold CBAY as of Q1 2017.

Kingdon Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2017 after selling out during the quarter.
Kingdon Capital Management sold 941,348 Cymabay Therapeutics shares in Q1 2017, an estimated $1.63M.
Kingdon Capital Management first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 6 quarters.
Kingdon Capital Management's Cymabay Therapeutics position peaked at $1.86M in Q3 2016.
34 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2017.

Based on Kingdon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.